Pfizer is expected to get authorization for their vaccine within the next few, after an experimental COVID-19 vaccine from Pfizer and BioNTech was 95% effective in results from a study. If all goes smoothly, the company would be on track to start distributing the vaccine before the end of this year.
If the vaccine gets authorized by the Food and Drug Administration, Pfizer is projected to have 50 million doses available by the end of 2020, and up to 1.3 billion by the end of 2021.
Pfizer said that researchers have not come across any serious safety issues, and that the vaccine has been well received after reviewing data from 8,000 study subjects.
The biggest side effect reported from this vaccine is fatigue, which 3.8% of subjects said they felt, and 2% of subjects reported headaches.
Pfizer Chief Executive Albert Bourla said, “The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic…we continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world.”
Pfizer reported their data shows that the vaccine is successful in preventing mild and severe forms of COVID-19.
The company is currently in the process of analyzing data from 19,000 study subjects and is compiling required documentation, before they can ask for authorization.
A few days ago, Moderna reported their vaccine was 94.5% effective on their preliminary results, giving a glimpse of hope that life will go back to “normal” soon.
